Scarica l'app Stockscreener
12.79
14.73%
-2.21
Dopo l'orario di chiusura:
12.80
0.01
+0.08%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BHVN Giù?
Forum
Previsione
Biohaven Ltd Borsa (BHVN) Ultime notizie
Biohaven’s Newly Out-Licensed Epilepsy Drug Put On A Partial Clinical Hold - insights.citeline.com
Biohaven: The Hold Isn't The Problem (Rating Downgrade) (NYSE:BHVN) - Seeking Alpha
BHVN Reiterated by HC Wainwright & Co. -- Price Target Maintained at $10 - GuruFocus
FDA pauses enrollment in Biohaven’s opakalim trials; pivotal readout remains on track - allsci.com
Why is Biohaven Pharmaceutical stock sliding today? - Investing.com
BHVN Stock Slips As Kv7 Deal Seen As Stopgap Move - StocksToTrade
BHVN Stock Slips As SK Deal Seen As Buying Time - timothysykes.com
Baird reiterates Biohaven stock rating after regulatory update - Investing.com
Baird reiterates Biohaven stock rating after regulatory update By Investing.com - Investing.com Canada
US FDA pauses new enrollment in Biohaven's epilepsy drug trials - Reuters
Why Is Biohaven Stock Tumbling Today?Biohaven (NYSE:BHVN) - Benzinga
FDA Places Partial Clinical Hold on Biohaven’s BHV-7000 Epilepsy Enrollment - Minichart
Biohaven Shares Fall 17% After FDA Places Partial Hold on BHV-7000 Trials - Yahoo Finance
BHVN Stock Crashes 10% – Why Did FDA Put Biohaven’s Epilepsy Trial On Partial Hold? - Yahoo Finance
FDA places partial hold on Biohaven’s epilepsy drug - Yahoo Finance
Biohaven stock tumbles after pausing trial enrollment By Investing.com - Investing.com Australia
Biohaven stock tumbles after pausing trial enrollment - Investing.com
Biohaven faces partial FDA hold on BHV-7000 program - TipRanks
Form 8K Biohaven Pharmaceutical Holding Co For: 10 September By Investing.com - Investing.com Canada
Biohaven pauses new enrollment in epilepsy trials after FDA partial clinical hold - Investing.com Canada
Is Biohaven (BHVN) Priced At A Premium After Its 36% Rise? - simplywall.st
Technical Reactions to BHVN Trends in Macro Strategies - Stock Traders Daily
BHVN Stock On Track For Best Day In Over 2 Months After SK Biopharmaceuticals Licenses Epilepsy Drug: Retail Now Awaits Obesity Trial Readout - Stocktwits
BHVN Stock Builds Momentum Ahead Of Multiple H2 2026 Clinical Data Readouts - Stocktwits
Biohaven Pharma stock falls after RBC Capital downgrade By Investing.com - Investing.com India
Biohaven Stock Seen Range-Bound as Near-Term Catalysts Fade, RBC Says - marketscreener.com
Biohaven stock downgraded at RBC Capital Markets (BHVN:NYSE) - Seeking Alpha
Biohaven Pharma stock falls after RBC Capital downgrade - Investing.com
BHVN Downgraded by RBC Capital -- Price Target Lowered to $19.00 - GuruFocus
RBC Downgrades Biohaven to Sector Perform From Outperform, Cuts Price Target to $19 From $23, Keeps Speculative Risk - marketscreener.com
Biohaven Shares Fall After RBC Downgrades Stock and Cuts Price Target - Yahoo Finance
Why is Biohaven Pharmaceutical stock sliding today? By Investing.com - Investing.com Canada
RBC Capital downgrades Biohaven Pharma stock rating on valuation By Investing.com - Investing.com South Africa
Did Biohaven’s Kv7 Deal With SK Biopharmaceuticals Just Reshape BHVN’s Risk And Funding Profile? - simplywall.st
Biohaven (BHVN) Cashes In On Its Biggest Epilepsy Bet - Yahoo Finance
With an ion the bottom line, Biohaven signs SK epilepsy deal - BioWorld News
Biohaven (BHVN) Is Up 11.3% After Out-Licensing Kv7 Platform To SK Biopharm For Up To $795M - webull.com
Is Biohaven (BHVN) A Bargain On Its SK Biopharma Licensing Deal? - simplywall.st
Precision Trading with Biohaven Ltd. (BHVN) Risk Zones - Stock Traders Daily
Why Biohaven Stock Was Rocking the Market This Week - Yahoo Finance
Biohaven advances key drug trials and secures $350M deal with SK Biopharmaceuticals - Pluang
Biohaven: Sale Of Opakalim Rights To SK Biopharmaceuticals Makes Sense On Many Levels - Seeking Alpha
BHVN Stock Soars 18% on $795M Out-Licensing Deal for Epilepsy Program - Yahoo Finance
Why Biohaven Ltd. (BHVN) Stock Is Up Today - Quiver Quantitative
Biohaven Ltd. And SK Biopharmaceuticals Co., Ltd. Enter Into Global Licensing Agreement For Kv7 Ion Channel Platform And Opakalim - marketscreener.com
Biohaven stock surges 7% on SK Biopharmaceuticals deal By Investing.com - Investing.com Australia
Biohaven licenses Kv7 epilepsy platform to SK Biopharma for up to $795M - StreetInsider
SK Bio taps up Biohaven for Kv7 platform and epilepsy drug in USD 795m deal - allsci.com
Biohaven stock surges 7% on SK Biopharmaceuticals deal - Investing.com
Biohaven (NYSE: BHVN) offloads epilepsy drug costs in rich global licensing pact - Stock Titan
12 Health Care Stocks Moving In Wednesday's Intraday SessionBiohaven (NYSE:BHVN), SCYNEXIS (NASDAQ:SCY - Benzinga
Biohaven, Yale win $4M judgment in trade secret case By Investing.com - Investing.com Nigeria
Federal Court Enters Judgment Confirming RA Capital and Avilar Therapeutics Willfully and Maliciously Misappropriated Trade Secret Developed at Yale, Formalizing $4 Million Award to Biohaven and Yale University - PR Newswire
Biohaven’s epilepsy drug deal could bring $400 million in cash from SK Biopharmaceuticals - Stock Titan
Is Biohaven (BHVN) Undervalued Following Its Latest Earnings Loss Improvement? - Sahm
Why Biohaven (BHVN) Is Down 9.1% After Reporting Narrower Q2 and H1 Net Losses - Sahm
Price to earnings forward of Biohaven Ltd. – NYSE:BHVN - TradingView
HC Wainwright Decreases Earnings Estimates for Biohaven - MarketBeat
NewEdge Wealth LLC Invests $3.66 Million in Biohaven Ltd. $BHVN - MarketBeat
Biohaven Ltd. (NYSE:BHVN) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Piper Sandler Maintains Biohaven(BHVN.US) With Buy Rating, Maintains Target Price $30 - Moomoo
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):